Pfizer Aktie

34,40EUR -0,30EUR -0,86%
<
News + Analysen
News + Adhoc
Analysen
Kursziele
>
<
Unternehmen
Termine
Profil
>
<
zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs
>

Aktionärsstruktur

Inhaber in %
Freefloat 1,00
Vanguard Group, Inc. (Subfiler) 0,08
The Vanguard Group, Inc. 0,08
SSgA Funds Management, Inc. 0,05
State Street Corp. 0,05
Capital Research & Management Co. (World Investors) 0,03
Vanguard Total Stock Market Index Fund 0,03
Wellington Management Co. LLP 0,02
T. Rowe Price Associates, Inc. (Investment Management) 0,02
Geode Capital Management LLC 0,02
Vanguard 500 Index Fund 0,02
BlackRock Fund Advisors 0,02
BlackRock Institutional Trust Co. NA 0,02
Legal & General Group PLC (13F Subfiler) 0,01
Merrill Lynch, Pierce, Fenner & Smith, Inc. (Old) 0,01

*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.

Personal

2014 2015 2016 2017 2018
Personal am Ende des Jahres 0 0 0 0 0
Umsatz pro Mitarbeiter in Mio. EUR 633 524 904 214 559,00 498 988 764 044 944,00 54 739 896 373 057,00 582 549 889 135 255,00 580 595 238 095 238,00

Bilanz (in Mio. EUR) - Aktiva

2014 2015 2016 2017 2018
Summe Umlaufvermögen 57 702 43 804 38 949 41 141 49 926
Summe Anlagevermögen 107 983 103 698 101 630 114 799 105 147
Summe Aktiva 169 274 167 460 171 615 171 797 159 422

Bilanz (in Mio. EUR) - Passiva

2014 2015 2016 2017 2018
Gesamtverschuldung/ -verbindlichkeiten 36 682 38 978 42 086 43 491 41 740
Summe Fremdkapital 97 652 102 462 111 775 100 141 95 664
Summe Eigenkapital 71 622 64 998 59 840 71 656 63 758
Summe Passiva 169 274 167 460 171 615 171 797 159 422

Adresse

235 East 42nd Street, 10017-5755 New York
Telefon 1.212.733.2323
Internet http://www.pfizer.com

Management

Albert Bourla
Director, Chief Executive & Operating Officer
Alexander Roderick MacKenzie
Chief Development Officer & Executive VP
Andy Schmeltz
President-US Oncology Business Unit
Angela Hwang
Group President-Biopharmaceuticals
Dan R. Littman
Independent Director
Dawn Rogers
Chief Human Resources Officer & EVP
Denise Bruns
Late-Phase Development Group Leader
Douglas M. Lankler
Executive Vice President & General Counsel
Frank A. D'Amelio
Chief Financial Officer & EVP-Business Operations
Freda C. Lewis-Hall
Chief Patient Officer & Executive Vice President
Helen H. Hobbs
Independent Director
Ian C. Read
Executive Chairman
James C. Smith
Independent Director
James Marshall Kilts
Independent Director
John D. Young
Group President-Chief Business Officer
John DeYoung
Vice President-Worldwide Business Development
John E. Sorrentino
VP & COO-Vaccine Research & Development
Joseph J. Echevarria
Independent Director
Lidia L. Fonseca
Chief Technology Officer & EVP
Loretta V. Cangialosi
Senior Vice President & Controller
Margaret M. Madden
Secretary, Chief Governance Counsel & Senior VP
Margi McLoughlin
Executive Director-World Wide Business Development
Mark Swindell
President-Vaccines
Mark White
Senior Director & Group Leader-Pain Therapeutics
Michael Goettler
Executive Vice President
Mikael Dolsten
Chief Scientific Officer
Monika A. Vnuk
Vice President-Worldwide Business Development
Rady A. Johnson
Chief Compliance & Risk Officer, Executive VP
Ronald E. Blaylock
Independent Director
Sally Susman
Chief Corporate Affairs Officer & Executive VP
Scott Gottlieb
Director
Shantanu Narayen
Lead Independent Director
Suzanne Nora Johnson
Independent Director
Tamas Koncz
Senior Medical Director
W. Don Cornwell
Independent Director